Janssen drops US lawsuit against Samsung Bioepis' Remicade copy

  • Johnson & Johnson's Janssen Biotech has withdrawn litigation seeking to block Samsung Bioepis from marketing a biosimilar of Remicade in the US, as reported NASDAQ Tuesday.

  • "Janssen's withdrawal of the lawsuit marks a positive step towards improving patient access to biosimilars in the [US]," remarked Samsung Bioepis spokesman Mingi Hyun.

  • Samsung Bioepis and partner Merck & Co. launched Renflexis as a biosimilar of Remicade in the US in July.

  • Remicade amasses around $5 billion in annual revenue in the US.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>